FAIRFIELD, CT, June 03, 2013 (Press-News.org) In their May 17th "Digital Crave" shopping blog, Yahoo! included the new ThiPad thigh-mounted tablet stand in a piece titled "The Worst iPad Accessories--Ever."
"And they did us a favor," says Jerry McTigue, creator of the ThiPad. "Because the hundreds of readers who went to the ThiPad.com website to see just how bad a product it was, actually discovered how good it was. And they started buying it."
McTigue believes that if the ThiPad can gain converts with horrible publicity like that, there's no telling what it would do if given a fair evaluation. He maintains that the so-called reporter never bothered to obtain a sample of the product and try it out. "Rather, he based his snide judgements on website images and a pre-prejudiced need to round up targets for a snark attack," says McTigue. "This is the kind of shoot-from-the-hip, junk journalism that's rampant on the Internet, intended to throw red meat to ridicule-hungry trolls. Yet it can be potentially devastating to people making an honest living creating products that deliver real value to users."
The ThiPad Hands-Free Tablet Stand straps securely to the leg just above the knee, with a non-slip surface that snugly holds any-sized tablet computer, including iPads, Kindles, Nooks, Androids, smartphones, and other mobile devices, in their cases or out. It provides hours of comfortable viewing, working, typing, playing games, or practicing with a musical instrument, without tying up the hands or tiring out the arms.
McTigue invites reputable journalists and media organizations to request a review sample of the product so they can give it a fair and impartial test run. "Then they can love it, hate it, pan it, or praise it, as they see fit," he says. "But we think they'll be surprised at how securely the new ThiPad fits and how beautifully it performs."
To request a review sample, contact inquiry@thipad.com or 203-254-7789. To learn more visit http://thipad.com.
ThiPad.com is the creator and manufacturer of the new ThiPad Hands-Free Tablet Stand.
"Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet Stand
Included among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.
2013-06-03
ELSE PRESS RELEASES FROM THIS DATE:
Some patients with treatment-resistant colorectal cancers may have a new option
2013-06-02
PHILADELPHIA — A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.
The MET gene is known to be amplified in about ...
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
2013-06-02
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Chicago, Illinois—GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is ...
New cancer drug shows promise for treating advanced melanoma
2013-06-02
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr. Antoni Ribas, professor of medicine in the UCLA division of hematology-oncology, who led the research. Following Ribas' presentation, the study was published online ahead of press in the New England Journal of Medicine. ...
Test helps target glioblastoma patients most likely to benefit from bevacizumab
2013-06-02
CHICAGO, IL – A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology.
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants ...
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
2013-06-02
CHICAGO, JUNE 2, 2013 — The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Several patients experienced tumor shrinkage of more than 80 percent within ...
Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
2013-06-02
Chicago, IL – The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.
Glioblastoma is both the most common and lethal form of brain ...
US oncologists report high career satisfaction, yet many suffer symptoms of burnout
2013-06-02
CHICAGO -- Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.
"Oncology can be a tremendously rewarding area of medicine, but caring for patients with cancer is also demanding and stressful," says lead author Tait Shanafelt, M.D., a Mayo Clinic hematologist/oncologist. "Oncologists work long hours, supervise the administration of highly toxic ...
Abnormalities in HER2 gene found in wide variety of advanced cancers
2013-06-02
(CHICAGO) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use.
"No ...
Therapy that heats and destroys bone tumors eases patients' pain
2013-06-02
(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, ...
Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients
2013-06-02
CHICAGO – The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4).
If approved for use in thyroid cancer patients by the Food and Drug Administration, sorafenib (Nexavar), a kinase inhibitor that mediates tumor ...
LAST 30 PRESS RELEASES:
Researchers generate lung cells from mouse fibroblasts in just 7 to 10 days
Prizewinner’s research reveals how immune responses to friendly skin microbiota could pave way for novel vaccination responses
Old aerial photos give scientists a new tool to predict sea level rise
20 million for courageous research at ISTA
Ships trigger high and unexpected emissions of the greenhouse gas methane
Optimizing laser irradiation: An in-silico meta-analysis of skin discoloration treatment
Climate crisis could force wild vanilla plants and pollinating insects apart, threatening global supply
Teens report spending 21% of each driving trip looking at their phone
Study explores the ‘social norms’ of distracted driving among teens
Diver-operated microscope brings hidden coral biology into focus
Enhancing the “feel-good” factor of urban vegetation using AI and street view images
A single genetic mutation may have made humans more vulnerable to cancer than chimpanzees
Innovative nanocomposite hydrogel shows promise for cartilage regeneration in osteoarthritis treatment
2025 Guangci Laboratory Medicine Innovation and Development Conference
LabMed Discovery is included in the ICI World Journals database
LabMed Discovery is included in the China Open Access Journal (COAJ) database
Vaccination support program reduces pneumonia-related mortality by 25 percent among the elderly
Over decades, a healthy lifestyle outperforms metformin in preventing onset of Type 2 diabetes
Mental health disorders, malaria, and heart disease most affected by covid pandemic
Green transition will boost UK productivity
Billions voted in 2024, but major new report exposes cracks in global democracy
Researchers find “forever chemicals” impact the developing male brain
Quantum leap in precision sensing across technologies
Upgrading biocrude oil into sustainable aviation fuel using zeolite-supported iron-molybdenum carbide nanocatalysts
For effective science communication, ‘just the facts’ isn’t good enough
RT-EZ: A golden gate assembly toolkit for streamlined genetic engineering of rhodotorula toruloides
Stem Cell Reports announces five new early career editors
Support networks may be the missing link for college students who seek help for excessive drinking
The New England Journal of Medicine shines spotlight on forensic pathology
Scientists discover protein that helps lung cancer spread to the brain
[Press-News.org] "Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet StandIncluded among the "Worst Ever" iPad accessories by a Yahoo! shopping blog, the ThiPad Hands-Free Tablet Stand actually experienced a sharp spike in sales when intrigued readers flocked to the ThiPad.com site.